title: Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
abstract: OBJECTIVE
  The aim of this study was to evaluate the survival benefit of adjuvant chemotherapy with etoposide, leucovorin and 5-fluorouracil (ELF) in gastric cancer patients undergoing previous surgery with a curative intent.
  
  
  METHODS
  The clinical outcome of 49 patients with resected gastric cancer treated with adjuvant chemotherapy was compared with that of 85 surgically treated historical controls who did not receive any adjuvant treatment. The chemotherapy regimen consisted of six cycles of daily 1-hour intravenous infusions of folinic acid 100 mg/m2 and 5-FU 400 mg/ m2, and a 2-hour infusion of etoposide 100 mg/m2, for three days every 28 days.
  
  
  RESULTS
  The 5-year relapse-free survival was 32% in the adjuvant arm and 27% in the control arm (p = 0.6). At the last follow-up, there were 32 deaths in the adjuvant arm and 60 in the control arm. The median duration of survival was respectively 23 and 19 months, and the 5-year survival rates were 34% and 29% (p = 0.4). The chemotherapy was well tolerated.
  
  
  CONCLUSIONS
  Our data suggest that ELF adjuvant treatment is a safe and well tolerable combination chemotherapy in patients with resected gastric cancer, but it does not seem to improve prognosis in comparison with historical controls.
authors.affiliation: Department of Medical Oncology, University of Siena, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.forename: Marianna
authors.initials: M
authors.lastname: Sabatino
authors.forename: Franco
authors.initials: F
authors.lastname: Roviello
authors.forename: Daniele
authors.initials: D
authors.lastname: Marrelli
authors.forename: Giacomo
authors.initials: G
authors.lastname: Nastri
authors.forename: Stefania
authors.initials: S
authors.lastname: Marsili
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Correale
authors.forename: Daniele
authors.initials: D
authors.lastname: Pozzessere
authors.forename: Simona
authors.initials: S
authors.lastname: Messinese
authors.forename: Antonio
authors.initials: A
authors.lastname: De Martino
authors.forename: Francesco
authors.initials: F
authors.lastname: Tani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Marzocca
authors.forename: Marco
authors.initials: M
authors.lastname: Lorenzi
authors.forename: Serenella
authors.initials: S
authors.lastname: Civitelli
authors.forename: Gabriello
authors.initials: G
authors.lastname: Tanzini
authors.forename: Enrico
authors.initials: E
authors.lastname: Pinto
authors.forename: Guido
authors.initials: G
authors.lastname: Francini
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005743:Gastrectomy; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D058766:Levoleucovorin; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*
chemical_list: D005047:Etoposide; D058766:Levoleucovorin; D002955:Leucovorin; D005472:Fluorouracil